Acquired Hemophilia A Successfully Treated with Rituximab

Acquired hemophilia A (AHA) is a rare bleeding disorder due to the development of specific autoantibodies against factor VIII. The anti-CD20 monoclonal antibody Rituximab has been proven to be effective in obtaining a long-term suppression of inhibitors of AHA, besides other immunosuppressive standa...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Mediterr J Hematol Infect Dis
Prif Awduron: D’Arena, Giovanni, Grandone, Elvira, Di Minno, Matteo Nicola Dario, Musto, Pellegrino, Di Minno, Giovanni
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Università Cattolica del Sacro Cuore 2015
Pynciau:
Case Report
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4344169/
https://ncbi.nlm.nih.gov/pubmed/25745551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4084/MJHID.2015.024
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg